Category: 28697-07-6

Related Products of 28697-07-6, Catalysts are substances that increase the reaction rate of a chemical reaction without being consumed in the process. 28697-07-6, Name is N-Cbz-2-Piperidinecarboxylic acid, molecular formula is C14H17NO4. In a Patent，once mentioned of 28697-07-6

Disclosed herein are novel benzoimidazoles and pharmaceutical compositions comprising at least one such novel benzoimidazoles, processes for the preparation thereof, and the method for using the same in therapy. In particular, disclosed herein are certain novel benzoimidazoles that are useful for inhibiting indoleamine 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Related Products of 28697-07-6, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 28697-07-6, in my other articles.

Reference：
Piperidine – Wikipedia,
Piperidine | C5H21431N – PubChem

 

Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 28697-07-6, molcular formula is C14H17NO4, introducing its new discovery. Formula: C14H17NO4

The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as Via receptor modulators, and in particular as Via receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, Formula: C14H17NO4, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 28697-07-6

Reference：
Piperidine – Wikipedia,
Piperidine | C5H21411N – PubChem

 

Related Products of 28697-07-6, Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 28697-07-6, Name is N-Cbz-2-Piperidinecarboxylic acid,introducing its new discovery.

The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

If you’re interested in learning more about 91419-52-2, below is a message from the blog Manager. Related Products of 28697-07-6

Reference：
Piperidine – Wikipedia,
Piperidine | C5H21412N – PubChem

 

Chemistry is an experimental science, category: piperidines, and the best way to enjoy it and learn about it is performing experiments.Introducing a new discovery about 28697-07-6, Name is N-Cbz-2-Piperidinecarboxylic acid

The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula (I) wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as Via receptor modulators, and in particular as Via receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. category: piperidines, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 28697-07-6, in my other articles.

Reference：
Piperidine – Wikipedia,
Piperidine | C5H21416N – PubChem

 

Chemistry is an experimental science, Formula: C14H17NO4, and the best way to enjoy it and learn about it is performing experiments.Introducing a new discovery about 28697-07-6, Name is N-Cbz-2-Piperidinecarboxylic acid

NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST

The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; R1 represents an optionally substituted alkyl group or the like; R2 represents a halogen atom or the like; and R3 is an alkyl group substituted with an optionally substituted aryl group or the like, and R4 is a hydrogen atom or the like; or R3 and R4 are terminally attached to each other, and together with the nitrogen atom to which they are attached, form an optionally substituted nitrogen-containing aliphatic heterocyclic ring that may partially contain a double bond; or to a pharmaceutically acceptable salt thereof.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Formula: C14H17NO4, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 28697-07-6, in my other articles.

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H21406N – PubChem

 

Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 28697-07-6, molcular formula is C14H17NO4, introducing its new discovery. Computed Properties of C14H17NO4

HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES

The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula I wherein R1, R2 and R3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, Computed Properties of C14H17NO4, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 28697-07-6

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H21415N – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.28697-07-6,N-Cbz-2-Piperidinecarboxylic acid,as a common compound, the synthetic route is as follows.

Example 27N-(3,5-Dichloroisonicotinoyl)-4-(2-piperidin-2-yl-3H-imidazo[4,5-b]pyridin-3-yl)-L- phenylalanine (Compound 11) To Intermediate 2 (3.41g) in DCM (40ml) is added 1-Cbz-2-piperidinecarboxylic acid (4.48g), HOBt (346mg) and EDC (4.88g). The reaction is stirred at room temperature for 3 days. The reaction is partitioned between DCM (40ml) and water (40ml) and the organic layer washed with 10% AcOH solution (40ml). The solvent is removed in vacuo and the residue dissolved in AcOH (12ml) and heated in a microwave at 1200C for 10 minutes. The mixture is evaporated to dryness in vacuo and partitioned between EtOAc (40ml) and saturated NaHCO3 (40ml), the organic layer is dried over Na2SO4, filtered, evaporated to dryness and the residue purified by chromatography on silica eluting with EtOAc/heptane. To a portion of the purified material (1.25g) in DCM (20ml) is added TFA (1.51 ml) at room temperature. The reaction is stirred at room temperature for 20 hours. The reaction is partitioned between DCM (50ml) and saturated NaHCO3 (50ml), dried over Na2SO4, filtered and the evaporated to dryness. To a portion of the obtained material (348mg) in DCM (4ml) is added DIPEA (138mul) followed by 2,6-dichloroisonicotinoyl chloride (169mg) in DCM (2ml). The reaction is stirred at room temperature for 1 hour. The reaction is partitioned between DCM (40ml) and water (40ml). The organic layer is dried over Na2SO4, filtered and evaporated to dryness in vacuo and the residue purified by chromatography on silica eluting with EtOAc/heptane. To the purified material (310mg) in EtOH (10ml) under N2(g) is added 10% Pd on carbon (50mg). The mixture is flushed with H2(g) and stirred at atmospheric pressure for 3 days. The mixture is filtered through a pad of celite, and the filtrate evaporated to dryness in vacuo. The crude material is dissolved in THF (4ml) and added slowly over 1 hour to a stirred solution of NaOH (2.0M, 5ml). Once addition is complete the reaction is stirred at room temperature for 1 hour, the reaction mixture acidified to acidic pH with HCI (6.0M), concentrated in vacuo and purified by preparative HPLC (Method C) to afford the title compound as a white solid (61 mg, 1%). LCMS (Method A) 539 [M+H] RT 1.72 mins. 1H NMR 300MHz (CDCI3) .81.10-1.41 (m, 2H), 1.43-1.60 (m, 2H), 1.70 (m, 2H), 1.88 (d, 1 H), 2.41 (m, 1 H), 3.00 (m, 2H), 3.39 (d, 1 H), 3.75 (d, 1 H), 4.77 (m, 1 H), 7.25 (m, 3H), 7.50 (d, 2H), 8.00 (d, 1 H), 8.09 (dd, 1 H), 8.40 (s, 2H), 28697-07-6

The synthetic route of 28697-07-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UCB PHARMA, S.A.; WO2008/64823; (2008); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.28697-07-6,N-Cbz-2-Piperidinecarboxylic acid,as a common compound, the synthetic route is as follows.

General procedure: (i) A solution of 2,6-difluorobenzoic acid (0.32 mol) in thionyl chloride (100 mL) was heated to reflux for 2 h. The resulting solution was concentrated and acid chloride intermediate was used in the next step without additional purification. To a solution of the acid chloride in anhydrous THF (100 mL) was added ammonium hydroxide (79 mL) at 0 C. After stirring at room temperature for 0.5 h, the reaction mixture was concentrated under reduced pressure. Then the reaction mixture was poured into cooled water (50 mL), extracted with ethyl acetate (100 mL x 3), and washed with brine (150 mL x 2). The organic layer was dried and concentrated to give the intermediate 2 in 90% yield which used in next step without purification. (ii) To a solution of 2,6-difluorobenzamide (0.28 mol) in concentrated sulfuric acid (90 mL) was added fuming nitric acid (12 mL) by dropwise under 0 C. The mixture was stirred for 2 h at room temperature. The pH was adjusted to 6 with 30% sodium hydroxide solution, then filtered and the filtrate was extracted with ethyl acetate (100 mL x 3),and washed with brine (150 mL x 2). The organic layer was dried and concentrated in vacuo to give the intermediate 3 as yellow solid in 91.40%yield. (iii) To a solution of 2,6-difluoro-3-nitrobenzamide (0.25 mol) in ethanol (300 mL) was added ammonium hydroxide (25 mL). The reaction mixture was stirred at room temperature overnight and the precipitate was collected by filtration, washed with isopropanol and dried in vacuum to give 4 31.5 g as yellow solid, yield 77.6%. (iv) A suspension of 2-amino-6-fluoro-3-nitrobenzamide (0.05 mol) in ethanol (100 mL) was reduced by hydrogen in the presence of palladium on carbon (10%, 1.00 g). After stirring at room temperature for 12 h, the reaction mixture was filtered. Solvent was removed under reduced pressure and the residue was subjected to silica gel column chromatography using dichloromethane/methanol (3:1) as eluent to give 55.00 g as light yellow solid, yield 58.9%. (v) To a solution of 3-pipecolinic acid (0.06 mol) and 2,3-diamino-6-fluorobenzamide (0.06 mol) in DMF (100 mL) was treated with PyBOP (0.06 mol) and N,N-diisopropylethylamine (0.18 mol).The reaction mixture was stirred at room temperature overnight. The solvent was removed using high vacuum. The residue was subjected to flash column chromatography using methylene chloride/methanol (30:1) to give the intermediate 6 as a white solid. The intermediate 6 was dissolved in glacial acetic acid (30 mL) and refluxed for 4 h until the reaction was complete (monitoring by TLC). The solvent was removed and the solid residue was purified by column chromatography using methylene chloride/methanol(80:1) as eluent to give pure 7a-7e in 50-72% yield. (vi) A solution of 7a-7e (25 mmol) in methanol (100 mL) was reduced with hydrogen in the presence of palladium on carbon (10%, 1.00 g). After stirring at room temperature for 12 h, the reaction mixture was filtered, and the filtrate was concentrated to give pure target compounds 8a-8e in 52-80% yield., 28697-07-6

The synthetic route of 28697-07-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Wang, Junwei; Wang, Xuyan; Li, Hui; Ji, Dezhong; Li, Yuyan; Xu, Yungen; Zhu, Qihua; Bioorganic and Medicinal Chemistry Letters; vol. 26; 16; (2016); p. 4127 – 4132;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem